We describe current findings on extravesicular tau, miRNAs, and mRNAs as diagnostic indicators in Alzheimer's disease and related tauopathies and evaluate the therapeutic potential of both endogenous and engineered EVs for delivering therapeutic agents or neuroprotective cargo. This evidence concerns the gene MAPT and tauopathy.